PAC113 Mouthrinse

PAC113 · Pacgen Biopharmaceuticals Corporation

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for PAC113 Mouthrinse, covering 2008-06-26 to 2008-06-26. Get the full timeline:

Most recent: Clinical Trial Update: Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis [Phase 2]